CLEAR·OCEAN

Damora Therapeutics, Inc. (DMRA): insiders bought $252,875 in open-market purchases, SEC filings show

September 29, 2026 · Automated from SEC filings

1 insider at Damora Therapeutics, Inc. (DMRA) reported open-market stock purchases totaling $252,875 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Jarrett Jennifer (director, officer: Director, President and CEO), who acquired 12,500 shares at $20.23 on September 25, 2026.

Reported open-market purchases

Source: SEC Form 4. Option grants and tax-withholding sales are excluded.

DateInsiderRoleSharesPriceValueSource
2026-09-25Jarrett Jenniferdirector, officer: Director, President and CEO12,500$20.23$252,875SEC Form 4

About the company

Damora Therapeutics, Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $1.3B, with shares trading near $20.75.

Sources

This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.